MX359515B - Derivados de benzotiofeno piperazina sustituidos como agentes antipsicoticos. - Google Patents

Derivados de benzotiofeno piperazina sustituidos como agentes antipsicoticos.

Info

Publication number
MX359515B
MX359515B MX2014002254A MX2014002254A MX359515B MX 359515 B MX359515 B MX 359515B MX 2014002254 A MX2014002254 A MX 2014002254A MX 2014002254 A MX2014002254 A MX 2014002254A MX 359515 B MX359515 B MX 359515B
Authority
MX
Mexico
Prior art keywords
piperazine
antipsychotic agents
benzothiophene derivatives
substituted benzothiophene
superior
Prior art date
Application number
MX2014002254A
Other languages
English (en)
Spanish (es)
Other versions
MX2014002254A (es
Inventor
Yamashita Hiroshi
Sakurai Yohji
Miyamoto Motoyuki
Nakamura Yuichi
Kuroda Hideaki
Minowa Takuya
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of MX2014002254A publication Critical patent/MX2014002254A/es
Publication of MX359515B publication Critical patent/MX359515B/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50Pyridazines; Hydrogenated pyridazines
    • A61K31/501Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/53751,4-Oxazines, e.g. morpholine
    • A61K31/53771,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541Non-condensed thiazines containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/66Phosphorus compounds
    • A61K31/675Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/695Silicon compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/18Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/20Hypnotics; Sedatives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic Table
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/18Compounds having one or more C—Si linkages as well as one or more C—O—Si linkages
    • C07F7/1804Compounds having Si-O-C linkages

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Anesthesiology (AREA)
  • Otolaryngology (AREA)
  • Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
MX2014002254A 2011-09-08 2012-09-07 Derivados de benzotiofeno piperazina sustituidos como agentes antipsicoticos. MX359515B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161532393P 2011-09-08 2011-09-08
PCT/JP2012/073556 WO2013035892A1 (en) 2011-09-08 2012-09-07 Piperazine- substituted benzothiophene derivatives as antipsychotic agents

Publications (2)

Publication Number Publication Date
MX2014002254A MX2014002254A (es) 2014-04-30
MX359515B true MX359515B (es) 2018-10-01

Family

ID=46940565

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014002254A MX359515B (es) 2011-09-08 2012-09-07 Derivados de benzotiofeno piperazina sustituidos como agentes antipsicoticos.

Country Status (31)

Country Link
US (9) US9260420B2 (OSRAM)
EP (1) EP2753617B9 (OSRAM)
JP (1) JP6193848B2 (OSRAM)
KR (1) KR101998441B1 (OSRAM)
CN (1) CN103781783B (OSRAM)
AR (1) AR087809A1 (OSRAM)
AU (1) AU2012305212B2 (OSRAM)
BR (1) BR112014005235B1 (OSRAM)
CA (1) CA2847339C (OSRAM)
CO (1) CO6930362A2 (OSRAM)
CY (1) CY1118753T1 (OSRAM)
DK (1) DK2753617T3 (OSRAM)
EA (1) EA028160B1 (OSRAM)
ES (1) ES2572934T3 (OSRAM)
HR (1) HRP20160824T2 (OSRAM)
HU (1) HUE027746T2 (OSRAM)
IL (1) IL231116B (OSRAM)
JO (1) JO3227B1 (OSRAM)
MX (1) MX359515B (OSRAM)
MY (1) MY196864A (OSRAM)
PH (1) PH12014500496A1 (OSRAM)
PL (1) PL2753617T3 (OSRAM)
PT (1) PT2753617T (OSRAM)
RS (1) RS54894B9 (OSRAM)
SG (2) SG10201601731RA (OSRAM)
SI (1) SI2753617T1 (OSRAM)
SM (1) SMT201600205B (OSRAM)
TW (1) TWI568728B (OSRAM)
UA (1) UA112993C2 (OSRAM)
WO (1) WO2013035892A1 (OSRAM)
ZA (1) ZA201401433B (OSRAM)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان
TW201332572A (zh) * 2011-12-28 2013-08-16 Otsuka Pharma Co Ltd 具有經取代的β-環糊精之藥物製劑
TWI562991B (en) * 2012-04-23 2016-12-21 Otsuka Pharma Co Ltd Dihydrate of benzothiophene compound or of a salt thereof, and process for producing the same
JOP20200109A1 (ar) 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP2014196292A (ja) * 2013-03-07 2014-10-16 大塚製薬株式会社 医薬
CN104447723A (zh) * 2014-11-28 2015-03-25 瑞阳制药有限公司 7-(4-(4-(苯并[b]噻吩基)-1-哌嗪基)丁氧基)-2(1H)-喹啉酮的制备方法
CN104829603A (zh) * 2015-05-19 2015-08-12 杭州新博思生物医药有限公司 A晶型依匹唑派盐酸盐及其制备方法
WO2017162536A1 (en) 2016-03-21 2017-09-28 H. Lundbeck A/S Vortioxetine prodrugs
PL233778B1 (pl) 2016-07-19 2019-11-29 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Sposob wytwarzania brekspiprazolu oraz zastosowanie zwiazkow posrednich w sposobie wytwarzania brekspiprazolu
US10583840B2 (en) * 2016-09-08 2020-03-10 Ford Motor Company Methods and apparatus to monitor an activity level of a driver
CN106699745A (zh) * 2016-12-14 2017-05-24 上海博志研新药物技术有限公司 一种依匹哌唑甲醇合物、晶型a、及其制备方法和应用
US20180265472A1 (en) * 2017-03-17 2018-09-20 Scinopharm Taiwan, Ltd. Process for preparing aripiprazole lauroxil and intermediates thereof
CN107628999B (zh) * 2017-10-25 2019-07-02 苏州华健瑞达医药技术有限公司 阿立哌唑十二烷酸酯的制备方法
CN109988162A (zh) * 2017-12-29 2019-07-09 武汉兴华智慧医药科技有限公司 一种依匹哌唑衍生物及其制备方法
CN110218209B (zh) * 2018-03-02 2022-09-30 上海现代药物制剂工程研究中心有限公司 一种依匹哌唑月桂酸酯的晶型a、其制备方法及应用
CN108947990A (zh) * 2018-07-20 2018-12-07 成都苑东生物制药股份有限公司 一种苯并噻吩类化合物的制备方法
US11981617B2 (en) 2019-01-11 2024-05-14 Alar Pharmaceuticals Inc. Ketamine pamoate and use thereof
CN116096715A (zh) * 2020-07-06 2023-05-09 泰科根公司 用于精神障碍或精神增强的有益苯并噻吩组合物
US11229644B1 (en) * 2020-12-31 2022-01-25 Lake O'hara Llc Methods of treating psychiatric disorders in obese patients with brexpiprazole
WO2022176017A1 (ja) * 2021-02-16 2022-08-25 大塚製薬株式会社 非晶質体及び当該非晶質体を含む組成物
CN114044772A (zh) * 2021-11-29 2022-02-15 浙江国邦药业有限公司 一种依匹哌唑合成方法及其中间体
CN116407539B (zh) * 2021-12-30 2025-01-10 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯的用途
CN116410186B (zh) * 2021-12-30 2025-03-04 上海现代药物制剂工程研究中心有限公司 依匹哌唑甲基脂肪酸酯及其制备方法
CN116891465A (zh) * 2022-03-30 2023-10-17 苏州旺山旺水生物医药有限公司 一类n-取代的喹啉酮化合物、其制备方法和用途
JP2023173950A (ja) * 2022-05-27 2023-12-07 同仁医薬化工株式会社 経口液剤
AU2024230422A1 (en) * 2023-02-27 2025-07-31 Otsuka Pharmaceutical Co., Ltd. Piperazine-substituted benzothiophenes for treatment of mental disorders
AU2024266462A1 (en) * 2023-05-02 2025-08-28 Otsuka Pharmaceutical Co., Ltd. Heterocyclic compound and use thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1546143A1 (en) * 2002-09-17 2005-06-29 Warner-Lambert Company LLC Heterocyclic substituted piperazines for the treatment of schizophrenia
AU2003295235B2 (en) 2002-12-27 2008-06-19 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
US7160888B2 (en) 2003-08-22 2007-01-09 Warner Lambert Company Llc [1,8]naphthyridin-2-ones and related compounds for the treatment of schizophrenia
US20050254575A1 (en) 2004-05-12 2005-11-17 Nokia Corporation Multiple interoperability points for scalable media coding and transmission
DE102004031052A1 (de) 2004-06-25 2006-01-12 Bühler AG System und Verfahren zur Mahlgut-Charakterisierung in einem Walzenstuhl
US7802705B2 (en) 2004-07-29 2010-09-28 Magie Pression Co., Ltd. Method for forming pleat on fabric composed of polylactic acid yarn, and pleated fabric
TWI320783B (en) * 2005-04-14 2010-02-21 Otsuka Pharma Co Ltd Heterocyclic compound
JP4315393B2 (ja) * 2005-04-14 2009-08-19 大塚製薬株式会社 複素環化合物
WO2006111246A1 (de) 2005-04-18 2006-10-26 Loi Thermprocess Gmbh Industrieofen
JP4540700B2 (ja) 2006-10-13 2010-09-08 大塚製薬株式会社 医薬
JP2011136906A (ja) * 2008-04-18 2011-07-14 Otsuka Pharmaceut Co Ltd 複素環化合物
ES2639065T5 (es) 2009-06-25 2023-01-30 Alkermes Pharma Ireland Ltd Compuestos heterocíclicos para el tratamiento de trastornos neurológicos y psicológicos
AU2010266040B2 (en) * 2009-06-25 2015-01-15 Alkermes Pharma Ireland Limited Prodrugs of NH-acidic compounds
EP2521711B1 (en) 2010-01-07 2017-08-16 Alkermes Pharma Ireland Limited Quaternary ammonium salt prodrugs
EP2585066B1 (en) 2010-06-24 2018-09-26 Alkermes Pharma Ireland Limited Prodrugs of nh-acidic compounds: ester, carbonate, carbamate and phosphonate derivatives
AU2011348085B2 (en) 2010-12-23 2016-12-08 Alkermes Pharma Ireland Limited Multi- API loading prodrugs
PL2685979T3 (pl) 2011-03-18 2017-02-28 Alkermes Pharma Ireland Limited Kompozycje farmaceutyczne do wstrzykiwania zawierające środek nierozpuszczalny w wodzie, środek przeciwpsychotyczny, laurynian sorbitanu i polisorbat 20
JO3227B1 (ar) * 2011-09-08 2018-03-08 Otsuka Pharma Co Ltd مشتقات بنزو ثيوفين بها استبدال ببرازين كعوامل مضادة للذهان

Also Published As

Publication number Publication date
HRP20160824T1 (hr) 2016-08-26
SG10201601731RA (en) 2016-04-28
EA028160B1 (ru) 2017-10-31
SMT201600205B (it) 2016-08-31
JP6193848B2 (ja) 2017-09-06
HK1195550A1 (zh) 2014-11-14
MX2014002254A (es) 2014-04-30
EA201490585A1 (ru) 2014-08-29
ES2572934T9 (es) 2017-05-08
IL231116B (en) 2019-09-26
KR20140069109A (ko) 2014-06-09
US20180318294A1 (en) 2018-11-08
HUE027746T2 (en) 2016-10-28
SI2753617T1 (sl) 2016-08-31
PT2753617T (pt) 2016-07-13
US20160143905A1 (en) 2016-05-26
NZ621837A (en) 2015-06-26
US9539252B2 (en) 2017-01-10
RS54894B9 (sr) 2019-12-31
BR112014005235A2 (pt) 2017-04-11
CA2847339A1 (en) 2013-03-14
JO3227B1 (ar) 2018-03-08
US9260420B2 (en) 2016-02-16
CN103781783B (zh) 2016-12-07
AU2012305212B2 (en) 2016-12-08
EP2753617B9 (en) 2017-01-25
IL231116A0 (en) 2014-04-30
BR112014005235B1 (pt) 2022-03-29
MY196864A (en) 2023-05-05
ZA201401433B (en) 2015-05-27
CO6930362A2 (es) 2014-04-28
TWI568728B (zh) 2017-02-01
US20170071933A1 (en) 2017-03-16
UA112993C2 (uk) 2016-11-25
EP2753617A1 (en) 2014-07-16
DK2753617T3 (en) 2016-07-25
JP2014526435A (ja) 2014-10-06
PH12014500496A1 (en) 2014-04-14
EP2753617B1 (en) 2016-04-13
ES2572934T3 (es) 2016-06-03
PL2753617T3 (pl) 2016-10-31
WO2013035892A1 (en) 2013-03-14
US20210052575A1 (en) 2021-02-25
CY1118753T1 (el) 2017-07-12
HRP20160824T2 (hr) 2017-05-19
US20200061056A1 (en) 2020-02-27
RS54894B1 (sr) 2016-10-31
TW201326160A (zh) 2013-07-01
US20230099694A1 (en) 2023-03-30
US20190167672A1 (en) 2019-06-06
KR101998441B1 (ko) 2019-07-09
US20180092907A1 (en) 2018-04-05
CN103781783A (zh) 2014-05-07
US20150045356A1 (en) 2015-02-12
CA2847339C (en) 2020-03-10
SG11201400148QA (en) 2014-03-28
AR087809A1 (es) 2014-04-16
AU2012305212A1 (en) 2014-04-24

Similar Documents

Publication Publication Date Title
PH12014500496A1 (en) Piperazine-substituted benzothiophene derivatives as antipsychotic agents
EA201290800A1 (ru) Гетероциклическое соединение
MY158982A (en) Heterocyclic compound
MX361499B (es) Baricitinib deuterado.
MY171055A (en) 3,5-disubstituted alkynylbenzene compound and salt thereof
JO3101B1 (ar) مشتقات بنزوثيازول كعوامل مضادة للسرطان
MY163187A (en) Novel imidazo-oxazine compound or salt thereof
TN2015000245A1 (en) Heterocyclic compound
IN2015DN01035A (OSRAM)
IN2015DN00598A (OSRAM)
MX2010002243A (es) Derivados fungicidas de 2-alquiltio-2-quinoliniloxi-acetamida.
MY161132A (en) Novel herbicides
MX2011007998A (es) Nuevos herbicidas.
IN2012DE00621A (OSRAM)
MX2011007932A (es) Herbicidas nuevos.
IN2012DE00620A (OSRAM)
TN2011000355A1 (en) Novel microbiocides
PH12015502665A1 (en) Improvements in or relating to organic compounds
PH12015501146A1 (en) Hydantoin derivative
IN2014DN10669A (OSRAM)
IN2012DN01223A (OSRAM)
UA79866U (ru) Применение 2-оксоиндолин-3-глиоксиловой кислоты в качестве средств с антидепрессивным действием
MX2010013184A (es) Compuesto heterocíclico.
UA82243U (ru) Соединение n-пара-бромфенил-3(-уридин-6'-амино)-сукцинимид с потенциальными физиологическими свойствами
UA101427C2 (en) Novel microbiocides

Legal Events

Date Code Title Description
FG Grant or registration